Trial results for the study NCT04848337 investigating the combination of pembrolizumab and lenvatinib in advanced/metastatic neuroendocrine prostate cancer were posted on ClinicalTrials.gov on 2026-02-12. The study reported a median radiologic progression-free survival (rPFS) of 4.0 months for patients in the treatment arm.
Background
The study NCT04848337 evaluated the combination of pembrolizumab (also known as Keytruda) and lenvatinib in patients with advanced or metastatic neuroendocrine prostate cancer.
Trial design
The Phase 2 study, NCT04848337, enrolled 45 participants with advanced or metastatic neuroendocrine prostate cancer. Patients received a combination of lenvatinib and pembrolizumab. Treatment was administered in 21-day cycles and continued until radiographic progression, intolerable toxicity, or patient/physician decision to discontinue protocol therapy, for a maximum of 35 cycles. The study did not list specific primary outcome measures in the provided data.
Key results
For the outcome of "Radiologic Progression Free Survival (rPFS)" in the Study Treatment Arm, the median was 4.0 months.
What this means
The median radiologic progression-free survival of 4.0 months observed in this Phase 2 study provides initial data on the activity of pembrolizumab and lenvatinib in advanced or metastatic neuroendocrine prostate cancer. These results may inform future research directions for combination therapies in this challenging disease setting.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT04848337, titled "Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer," were posted on 2026-02-12 on clinicaltrials.gov.